Does lapatinib work against HER2-negative breast cancers? - Wikidata - awgldk - TriplyDB

Does lapatinib work against HER2-negative breast cancers?

Does lapatinib work against HER2-negative breast cancers?

http://www.wikidata.org/entity/Q36253050

about

Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.

P2860

Q33648150-4E3CB819-DEE2-434A-8837-2E4345E86027 Q33648503-6439D390-BBB6-4CBA-9F02-CD3A68C6D257 Q35228445-9690EEC6-B517-4149-91DE-6BEFFDA470B1 Q36299102-0C0B0F72-6ABD-4EE6-8ECA-5BA4797318FF Q36311216-4AFC7FEA-2D38-4480-ADBC-1835F9076967 Q37632279-A643A780-96AA-4930-94A3-1515D9FA906F

P2860

Does lapatinib work against HER2-negative breast cancers?

http://www.wikidata.org/entity/Q36253050

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Does lapatinib work against HER2-negative breast cancers?

@ast

Does lapatinib work against HER2-negative breast cancers?

@en

type

label

Does lapatinib work against HER2-negative breast cancers?

@ast

Does lapatinib work against HER2-negative breast cancers?

@en

prefLabel

Does lapatinib work against HER2-negative breast cancers?

@ast

Does lapatinib work against HER2-negative breast cancers?

@en

P1433

Q36253050-F6622911-F132-49F6-8064-F796AFF307C3

P1476

Q36253050-8968E9BE-3D78-4B1D-A156-21DB9E1C9013

P2093

Q36253050-5F29F963-DA80-4F3D-BE40-8B8B206323F9

Q36253050-945CC892-E1A0-4D09-8BAE-6D54418E37DA

P2860

Q36253050-1DCBA18F-AD26-496E-9BD9-A5D4B37DDE06

Q36253050-392E3F58-799E-45FD-8A5C-F72A2BC866A6

Q36253050-3D68FE58-9A17-4BEB-B56F-740115226A09

Q36253050-626CEB32-F032-4122-A85C-04D4992EBA86

Q36253050-6EB9DA38-F8A7-4549-813B-85675C64C440

Q36253050-86BC799A-CAFF-4C4A-A35E-7935786BA64D

Q36253050-A2DBEF6D-54D8-4811-B366-4F311753B804

Q36253050-E2745065-B65D-432D-89CA-BD1F9ED730B6

Q36253050-ED0FB313-37B6-4F5E-A7E7-051CF988FC72

Q36253050-EE73FCA8-5E38-4F82-80B1-FA79BA2F9A1C

P304

Q36253050-7ED2728A-85A7-4F8B-9FB8-ECC1A9789656

P31

Q36253050-CBF11492-C58A-406A-93D3-72163DA7D578

P356

Q36253050-2BBF95E1-7D59-4FBE-88E2-16BC41DF1F42

P407

Q36253050-17483CD6-8E7F-44E6-944B-09342C88B0AA

P433

Q36253050-4B42273B-29D3-4F28-87EC-433399C9A6E3

P478

Q36253050-B8C78274-40E1-4478-BBDD-7CD78466A624

P577

Q36253050-23D3DF8C-71AB-4DA0-BCEA-3DFC1B4AA46A

P5875

Q36253050-14DAFFA4-EA0D-4B2F-A75B-96C51DD104E7

P698

Q36253050-E0777769-9990-4BB5-930D-E66C13F5E0F4

P932

Q36253050-8C528C6E-7428-428F-9574-3F5C375CC114

P356

1078-0432.CCR-09-3223

P1433

Clinical Cancer Research

P1476

Does lapatinib work against HER2-negative breast cancers?

@en

P2093

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Ingrid A Mayer

http://www.w3.org/2001/XMLSchema#string

P2860

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.

Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.

P304

1355-1357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-3223

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41548314

http://www.w3.org/2001/XMLSchema#string

P698

20179241

http://www.w3.org/2001/XMLSchema#string

P932

3448974

http://www.w3.org/2001/XMLSchema#string